Effect of notoginsenoside R1 on the synthesis of components of the fibrinolytic system in cultured smooth muscle cells of human pulmonary artery.
We have previously reported that notoginsenoside R1 (NG-R1) increases the synthesis of tissue-type plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 (PAI-1) activity in cultured human endothelial cells from different vascular sources. It was the aim of this study to investigate whether the effect of NG-R1 on the synthesis of components of the fibrinolytic system is also operative in another cell type of the blood vessel wall, the smooth muscle cell. Therefore cultured human pulmonary artery smooth muscle cells (HPASMCs) were treated with NG-R1. When the HPASMCs (passage 4 or 5) were conditioned with NG-R1, a dose (0.01-100 micrograms NG-R1/ml for 24 hrs.) dependent increase in t-PA an u-PA synthesis was observed, which was significant from 1 microgram NG-R1/ml on. t-PA antigen increased from 2.4 +/- 0.1 to 4.7 +/- 0.5 ng/10(5) cells/24 hrs.; u-PA antigen increased from 1.8 +/- 0.1 to 3.0 +/- 0.4 ng/10(5) cells/24 hrs. In contrast no change in PAI-1 antigen synthesis was seen in the conditioned media from NG-R1 treated HPASMCs. On Northern blot analysis of mRNA obtained from NG-R1-stimulated and control HPASMCs NG-R1 induced a significant increases in mRNA levels of t-PA and u-PA (180% and 200% of control value, respectively) at 100 micrograms NG-R1/ml while PAI-1 mRNA decreased slightly. In conclusion our data give evidence that NG-R1 can increase the fibrinolytic potential in cultured HPASMCs in vitro by increasing the production of t-PA and u-PA. If operative in vivo this effect of NG-R1 on the fibrinolytic system of SMCs might also contribute to the effect of the Chinese herb drug Panax notoginseng in the treatment of cardiovascular diseases.
Zhang
W J
WJ
Department of Vascular Biology and Thrombosis Research, University of Vienna, Austria.
Wojta
J
J
Binder
B R
BR
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D005342:Fibrinolysis / Q000187:drug effects*; D036145:Ginsenosides; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D010960:Plasminogen Activators / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D011651:Pulmonary Artery; D012333:RNA, Messenger / Q000378:metabolism; D012503:Saponins / Q000494:pharmacology*; D014158:Transcription, Genetic
D000972:Antineoplastic Agents, Phytogenic; D036145:Ginsenosides; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D012503:Saponins; D010960:Plasminogen Activators; C072936:notoginsenoside R1